Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

9.820 -0.150 (-1.50%)
Official Closing Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 Next >
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Third Quarter 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
Is This The Most Exciting Medical Breakthrough Of The Decade
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns.... 
Via FinancialNewsMedia
Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant
From Teva Pharmaceutical Industries Limited
Via Business Wire
Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Second Quarter 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Changes to Executive Management Team
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Bioeq Announce Commercial Partnership for Biosimilar
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
The Companies Tackling A Global Health Crisis
Via FinancialNewsMedia
Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.